<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="562" end="570" sStart="491" offset="71" sid="r8.suggest.v.0072" wn="3" wnkey="suggest%2:32:02::" text="Converging evidence from epidemiological and molecular studies suggests that infection of genital human papillomavirus (HPV) is causally linked to the development of CC [ 4 ] . Since only a small fraction of HPV-infected cervical intra-epithelial neoplastic (CIN) lesions progress to invasive cancer, these studies further suggest that in addition to HPV, other host genetic factors play a role in cervical carcinogenesis [ 5 ] . A number of molecular studies have identified genetic alterations in these two histologic types of CC and at various stages of precursor lesions [ 6 7 8 ] . Despite this molecular characterization, the genetic basis of CC initiation and progression is still very poorly understood." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="562" end="570" sStart="null" offset="71" sid="r8.suggest.v.0072" wn="3" wnkey="suggest%2:32:02::" text="Converging evidence from epidemiological and molecular studies suggests that infection of genital human papillomavirus (HPV) is causally linked to the development of CC [ 4 ] . Since only a small fraction of HPV-infected cervical intra-epithelial neoplastic (CIN) lesions progress to invasive cancer, these studies further suggest that in addition to HPV, other host genetic factors play a role in cervical carcinogenesis [ 5 ] . A number of molecular studies have identified genetic alterations in these two histologic types of CC and at various stages of precursor lesions [ 6 7 8 ] . Despite this molecular characterization, the genetic basis of CC initiation and progression is still very poorly understood." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="31743" end="31750" sStart="null" offset="20" sid="r8.suggest.v.0648" wn="3" wnkey="suggest%2:32:02::" text="Thus, our data also suggest that epigenetic changes that accompany methylation are common in CC and play critical role in CC development." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="20055" end="20062" sStart="null" offset="17" sid="r8.suggest.v.0252" wn="3" wnkey="suggest%2:32:02::" text="Thus, these data suggest that inactivation of the" />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="562" end="570" sStart="null" offset="71" sid="r8.suggest.v.0072" wn="3" wnkey="suggest%2:32:02::" text="Converging evidence from epidemiological and molecular studies suggests that infection of genital human papillomavirus (HPV) is causally linked to the development of CC [ 4 ] . Since only a small fraction of HPV-infected cervical intra-epithelial neoplastic (CIN) lesions progress to invasive cancer, these studies further suggest that in addition to HPV, other host genetic factors play a role in cervical carcinogenesis [ 5 ] . A number of molecular studies have identified genetic alterations in these two histologic types of CC and at various stages of precursor lesions [ 6 7 8 ] . Despite this molecular characterization, the genetic basis of CC initiation and progression is still very poorly understood." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="2101" end="2109" sStart="null" offset="322" sid="r8.suggest.v.0351" wn="3" wnkey="suggest%2:32:02::" text="The pattern of such promoter methylation has been noted to be non-random in various tumor types, while certain genes are commonly methylated in diverse tumor types [ 10 11 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG island methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="562" end="570" sStart="null" offset="71" sid="r8.suggest.v.0072" wn="3" wnkey="suggest%2:32:02::" text="Converging evidence from epidemiological and molecular studies suggests that infection of genital human papillomavirus (HPV) is causally linked to the development of CC [ 4 ] . Since only a small fraction of HPV-infected cervical intra-epithelial neoplastic (CIN) lesions progress to invasive cancer, these studies further suggest that in addition to HPV, other host genetic factors play a role in cervical carcinogenesis [ 5 ] . A number of molecular studies have identified genetic alterations in these two histologic types of CC and at various stages of precursor lesions [ 6 7 8 ] . Despite this molecular characterization, the genetic basis of CC initiation and progression is still very poorly understood." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1476-4598-2-24.anc" start="19784" end="19789" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Loss of function of CDH1 gene has been &lt;b&gt;shown&lt;/b&gt; to occur in widespread of epithelial tumor types by mutational or promoter hypermethylation mechanisms [ 11 20 ] . We have also identified loss of expression of CDH1 gene in 37." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1476-4598-2-24.anc" start="22069" end="22075" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Our semi-quantitative analysis of RARB gene expression by RT-PCR &lt;b&gt;showed&lt;/b&gt; down-regulated expression in all the eight cell lines analyzed whether or not the promoter methylated (Fig." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1476-4598-2-24.anc" start="19784" end="19789" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Loss of function of CDH1 gene has been &lt;b&gt;shown&lt;/b&gt; to occur in widespread of epithelial tumor types by mutational or promoter hypermethylation mechanisms [ 11 20 ] . We have also identified loss of expression of CDH1 gene in 37." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1476-4598-2-24.anc" start="22069" end="22075" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" text="Our semi-quantitative analysis of RARB gene expression by RT-PCR &lt;b&gt;showed&lt;/b&gt; down-regulated expression in all the eight cell lines analyzed whether or not the promoter methylated (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="33079" end="33084" sStart="null" offset="182" sid="r7.serve.v.0304" wn="1" wnkey="serve%2:42:03::" text="Particularly, if the present results are replicated and identified in precancerous lesions, this may be useful in predicting the high-risk lesions to progression and serve as targets of treatment." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="42490" end="42494" sStart="null" offset="0" sid="null" wn="1" wnkey="read%2:31:00::" text="All authors &lt;b&gt;read&lt;/b&gt; and approved the final manuscript." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="7354" end="7358" sStart="null" offset="0" sid="null" wn="1" wnkey="rate%1:28:00::" text="7%) and adenocarcinoma (AC; 100%) exhibited an overall high &lt;b&gt;rate&lt;/b&gt; of promoter methylation, we found statistically significant differences in various genes in these two histologic subsets (Table 2)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="7354" end="7358" sStart="null" offset="0" sid="null" wn="4" wnkey="rate%1:24:00::" text="7%) and adenocarcinoma (AC; 100%) exhibited an overall high &lt;b&gt;rate&lt;/b&gt; of promoter methylation, we found statistically significant differences in various genes in these two histologic subsets (Table 2)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="0" sid="null" wn="5" wnkey="poor%5:00:00:insufficient:00" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a &lt;b&gt;poor&lt;/b&gt; prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="541" sid="r7.poor.j.0653" wn="4" wnkey="poor%3:00:02::" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a poor prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="25344" end="25348" sStart="null" offset="148" sid="r7.poor.j.0012" wn="5" wnkey="poor%5:00:00:insufficient:00" text="A most significant finding was that overall promoter hypermethylation is associated with the progression and predicts significantly poor disease-free survival." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a &lt;b&gt;poor&lt;/b&gt; prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="541" sid="r7.poor.j.0653" wn="4" wnkey="poor%3:00:02::" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a poor prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="25344" end="25348" sStart="null" offset="148" sid="r7.poor.j.0012" wn="5" wnkey="poor%5:00:00:insufficient:00" text="A most significant finding was that overall promoter hypermethylation is associated with the progression and predicts significantly poor disease-free survival." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="0" sid="null" wn="1" wnkey="poor%5:00:00:unfortunate:00" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a &lt;b&gt;poor&lt;/b&gt; prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="25344" end="25348" sStart="null" offset="148" sid="r7.poor.j.0012" wn="5" wnkey="poor%5:00:00:insufficient:00" text="A most significant finding was that overall promoter hypermethylation is associated with the progression and predicts significantly poor disease-free survival." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="26998" end="27002" sStart="null" offset="0" sid="null" wn="5" wnkey="poor%5:00:00:insufficient:00" text="MGMT gene encodes O(6)-methylguanine-DNA methyltransferase and this enzyme effectively removes DNA adducts formed by alkylating agents [ 33 ] . Epigenetic gene silencing of MGMT confers enhanced sensitivity to alkylating-based chemotherapy, and lack of methylation associates with failure to respond to chemotherapy [ 34 35 ] . On the contrary, all patients that had MGMT promoter methylation were dead within 21 months of initial diagnosis, which predicts a &lt;b&gt;poor&lt;/b&gt; prognosis." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="25344" end="25348" sStart="null" offset="148" sid="r7.poor.j.0012" wn="4" wnkey="poor%3:00:02::" text="A most significant finding was that overall promoter hypermethylation is associated with the progression and predicts significantly poor disease-free survival." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24547" end="24553" sStart="null" offset="381" sid="r8.number.n.0094" wn="1" wnkey="number%1:07:00::" text="Such differences in the two major histologies have also been reported previously for DAPK , HIC1 , and APC genes [ 13 ] . However, we found CDH1 promoter methylation restricted to SCC in the present study, while Dong et al found methylation in both histological types [ 13 ] . This difference may be due to small number of AC patients we studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24547" end="24553" sStart="null" offset="381" sid="r8.number.n.0094" wn="1" wnkey="number%1:07:00::" text="Such differences in the two major histologies have also been reported previously for DAPK , HIC1 , and APC genes [ 13 ] . However, we found CDH1 promoter methylation restricted to SCC in the present study, while Dong et al found methylation in both histological types [ 13 ] . This difference may be due to small number of AC patients we studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24547" end="24553" sStart="null" offset="381" sid="r8.number.n.0094" wn="1" wnkey="number%1:07:00::" text="Such differences in the two major histologies have also been reported previously for DAPK , HIC1 , and APC genes [ 13 ] . However, we found CDH1 promoter methylation restricted to SCC in the present study, while Dong et al found methylation in both histological types [ 13 ] . This difference may be due to small number of AC patients we studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24547" end="24553" sStart="null" offset="381" sid="r8.number.n.0094" wn="1" wnkey="number%1:07:00::" text="Such differences in the two major histologies have also been reported previously for DAPK , HIC1 , and APC genes [ 13 ] . However, we found CDH1 promoter methylation restricted to SCC in the present study, while Dong et al found methylation in both histological types [ 13 ] . This difference may be due to small number of AC patients we studied." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="4008" end="4014" sStart="null" offset="85" sid="r9.normal.j.0381" wn="1" wnkey="normal%3:00:01::" text="Promoter hypermethylation was not found in the DNA isolated from normal cervical smears for any of the tested genes." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="35755" end="35761" sStart="null" offset="248" sid="r9.normal.j.0221" wn="1" wnkey="normal%3:00:01::" text="Genomic DNA was treated with sodium bisulphite as previously described [ 46 ] . Placental DNA treated in vitro with Sss I methyltransferase (New England Biolabs, Beverly, MA) and similarly treated normal lymphocyte DNA were used as controls for methylated and unmethylated templates, respectively." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="42072" end="42078" sStart="null" offset="52" sid="r9.normal.j.0066" wn="1" wnkey="normal%3:00:01::" text="Author 6 (JV) participated in collection of normal cervical specimens." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="42072" end="42078" sStart="null" offset="52" sid="r9.normal.j.0066" wn="3" wnkey="normal%3:00:03::" text="Author 6 (JV) participated in collection of normal cervical specimens." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="42072" end="42078" sStart="null" offset="52" sid="r9.normal.j.0066" wn="1" wnkey="normal%3:00:01::" text="Author 6 (JV) participated in collection of normal cervical specimens." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="3857" end="3863" sStart="null" offset="410" sid="r9.normal.j.0394" wn="2" wnkey="normal%3:00:02::" text="We examined the status of promoter hypermethylation of 16 genes ( CDH1 , DAPK , RARB , HIC1 , FHIT , RASSF1A , APC , CDKN2A , MGMT , BRCA1 , TP73 , TIMP3 , GSTP1 , MLH1 , p14 ARF , and RB1 ) in eight specimens of normal cervical squamous epithelia and 90 CC specimens." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="13849" end="13855" sStart="null" offset="274" sid="r9.normal.j.0190" wn="2" wnkey="normal%3:00:02::" text="To examine the biological role of promoter methylation in CC, we assessed the levels of mRNA by semi-quantitative RT-PCR in eight cell lines and compared with the respective control values obtained from the averages calculated from 2 normal cervix after normalization against ACTB . This analysis was performed on 7 genes ( CDH1 , DAPK , RARB , HIC1 , MGMT , RASSF1A , and MLH1 ) that exhibited methylation in one or more cell lines and primary tumors (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="34742" end="34748" sStart="null" offset="65" sid="r9.normal.j.0102" wn="2" wnkey="normal%3:00:02::" text="Eight normal cervical swabs, diagnosed on Pap smear as normal squamous epithelium, were collected in phosphate buffer saline from the patients attending Gynecology Clinic at the Columbia Presbyterian Medical Center, New York after appropriate informed consent." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="42072" end="42078" sStart="null" offset="52" sid="r9.normal.j.0066" wn="2" wnkey="normal%3:00:02::" text="Author 6 (JV) participated in collection of normal cervical specimens." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="20431" end="20435" sStart="null" offset="87" sid="r9.late.j.0500" wn="3" wnkey="late%5:00:00:past:00" text="Therefore, these data indicate that the methylation of CDH1 gene is a late event in the development of CC." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="2119" end="2125" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" text="The pattern of such promoter methylation has been noted to be non-random in various tumor types, while certain genes are commonly methylated in diverse tumor types [ 10 11 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG &lt;b&gt;island&lt;/b&gt; methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="30921" end="30928" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" text="Transcriptional silencing of genes resulting from DNA hypermethylation of CpG &lt;b&gt;islands&lt;/b&gt; is reversed by treatment with the hypo-methylating agent 5-aza-2'-deoxycytidine and HDAC-inhibiting agent n-butyrate in a dose and duration-dependent manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="2119" end="2125" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" text="The pattern of such promoter methylation has been noted to be non-random in various tumor types, while certain genes are commonly methylated in diverse tumor types [ 10 11 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG &lt;b&gt;island&lt;/b&gt; methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="30921" end="30928" sStart="null" offset="0" sid="null" wn="2" wnkey="island%1:06:00::" text="Transcriptional silencing of genes resulting from DNA hypermethylation of CpG &lt;b&gt;islands&lt;/b&gt; is reversed by treatment with the hypo-methylating agent 5-aza-2'-deoxycytidine and HDAC-inhibiting agent n-butyrate in a dose and duration-dependent manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-24.anc" start="38588" end="38593" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" text="The PCR products were run on 1.5% agarose gels, visualized by ethidium bromide staining and quantitated using the Kodak Digital &lt;b&gt;Image&lt;/b&gt; Analysis System (Kodak, New Haven, CT)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="5244" end="5248" sStart="null" offset="12" sid="r10.high.j.0661" wn="1" wnkey="high%3:00:02::" text="A high frequency of promoter methylation was detected in primary tumors for CDH1 (54." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="2082" end="2090" sStart="null" offset="303" sid="r11.function.n.0736" wn="3" wnkey="function%1:04:00::" text="The pattern of such promoter methylation has been noted to be non-random in various tumor types, while certain genes are commonly methylated in diverse tumor types [ 10 11 ] . The extent of aberrant promoter hypermethylation and its association with loss of gene function in cancer suggests that CpG island methylation is an important mechanism in inactivating tumor suppressor genes (TSGs)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="30559" end="30567" sStart="null" offset="134" sid="r11.function.n.0284" wn="2" wnkey="function%1:07:00::" text="Aberrant promoter methylation changes that occur in cancer are associated with transcriptional repression and loss of function of the methylated gene [ 9 ] . Since we found evidence of down-regulated expression of several methylated genes in CC cell lines, we tested to see if this down-regulation could be reactivated by methylation and HDAC-inhibiting agents." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="25708" end="25712" sStart="null" offset="2" sid="r9.fold.v.0324" wn="2147483645" wnkey="null" text="3 fold risk) genes." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="6172" end="6181" sStart="null" offset="48" sid="r8.1.different.j.0223" wn="1" wnkey="different%3:00:00::" text="9%) tumors, while other HPV types (20 different types) in 23 (25." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24074" end="24080" sStart="null" offset="95" sid="r10.common.j.0077" wn="4" wnkey="common%5:00:00:familiar:02" text="We found that methylation of HIC1 , APC , and BRACA1 genes was more common in AC while CDH1 promoter methylation was seen only in SCC." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24074" end="24080" sStart="null" offset="95" sid="r10.common.j.0077" wn="3" wnkey="common%5:00:00:shared:00" text="We found that methylation of HIC1 , APC , and BRACA1 genes was more common in AC while CDH1 promoter methylation was seen only in SCC." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24074" end="24080" sStart="null" offset="95" sid="r10.common.j.0077" wn="4" wnkey="common%5:00:00:familiar:02" text="We found that methylation of HIC1 , APC , and BRACA1 genes was more common in AC while CDH1 promoter methylation was seen only in SCC." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="24074" end="24080" sStart="null" offset="95" sid="r10.common.j.0077" wn="2" wnkey="common%3:00:01::" text="We found that methylation of HIC1 , APC , and BRACA1 genes was more common in AC while CDH1 promoter methylation was seen only in SCC." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="14587" end="14598" sStart="null" offset="225" sid="r11.combination.n.0724" wn="1" wnkey="combination%1:14:00::" text="Of the six cell lines with RARB gene methylated, three (HT-3, MS751, and ME-180) exhibited reactivation upon treatment with 5-Aza-2' deoxycytidine or n-butyrate alone or the combination of the two." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="6027" end="6038" sStart="null" offset="29" sid="r11.combination.n.0268" wn="1" wnkey="combination%1:14:00::" text="HPV 16 alone or in combination with other HPV types was found in 55 (61." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="16682" end="16693" sStart="null" offset="83" sid="r11.combination.n.0136" wn="1" wnkey="combination%1:14:00::" text="Treatment of 5-Aza-2' deoxycytidine or n-butyrate alone or the combination of both activated gene expression in all the cell lines, whether or not promoter had detectable methylation (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="27297" end="27308" sStart="null" offset="77" sid="r11.combination.n.0941" wn="1" wnkey="combination%1:14:00::" text="The standard treatment for advanced-stage cervix cancer has been the combination of radical surgery and radiotherapy [ 36 ] . The utility of cytotoxic chemotherapy in patients with advanced CC has been recognized recently [ 37 ] . Thus, the epigenetic gene silencing of MGMT , although in a small proportion, may serve as indicator of responsiveness to treatment with chemotherapeutic drugs that cause DNA adducts in CC." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="27196" end="27207" sStart="null" offset="182" sid="r11.combination.n.0701" wn="1" wnkey="combination%1:14:00::" text="A possible explanation for this failure to respond may be that all the four patients in the present study were treated only with radiotherapy with or without combination of surgery." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="28755" end="28766" sStart="null" offset="164" sid="r11.combination.n.0380" wn="1" wnkey="combination%1:14:00::" text="Our data, therefore, suggest that the CC patients showing RARB promoter methylation may benefit from targeted chemopreventive treatment of combination of retinoic acid, demethylating, and chromatin modifying agents that reactivate the gene expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="17281" end="17292" sStart="null" offset="189" sid="r11.combination.n.0329" wn="1" wnkey="combination%1:14:00::" text="Two of three cell lines with RASSF1A methylation and complete lack of expression reactivated upon treatment with 5-Aza-2' deoxycytidine alone or in combination with n-butyrate." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="15360" end="15371" sStart="null" offset="189" sid="r11.combination.n.0152" wn="1" wnkey="combination%1:14:00::" text="The SW756 cell line with methylation and one of the two unmethylated cell lines showed reactivated expression upon treatment with 5-Aza-2' deoxycytidine or in combination with n-butyrate, but not with n-butyrate alone." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="31178" end="31189" sStart="null" offset="67" sid="r11.combination.n.0053" wn="1" wnkey="combination%1:14:00::" text="We found that 5-Aza-2'-deoxycytidine treatment alone or in combination with n-butyrate resulted in reactivation of gene expression in most cell lines that showed promoter methylation." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="16177" end="16188" sStart="null" offset="222" sid="r11.combination.n.0369" wn="7" wnkey="combination%1:04:00::" text="Both methylated cell lines (HT-3 and SiHa) and three (C-33A, MS751, and ME-180) of the four unmethylated cell lines showed reactivation upon exposure to 5-Aza-2' deoxycytidine or in combination with n-butyrate." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="31178" end="31189" sStart="null" offset="67" sid="r11.combination.n.0053" wn="7" wnkey="combination%1:04:00::" text="We found that 5-Aza-2'-deoxycytidine treatment alone or in combination with n-butyrate resulted in reactivation of gene expression in most cell lines that showed promoter methylation." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="17705" end="17712" sStart="null" offset="73" sid="r11.absence.n.0941" wn="1" wnkey="absence%1:26:00::" text="One of the two methylated cell lines (CaSki) showed a complete absence of expression while the other methylated cell line (SW756) showed normal levels of expression." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="16282" end="16289" sStart="null" offset="76" sid="r11.absence.n.0602" wn="1" wnkey="absence%1:26:00::" text="One of the unmethylated cell lines (SW756) that showed a complete absence of expression did not reactivate after treatment." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="14972" end="14979" sStart="null" offset="55" sid="r11.absence.n.0029" wn="1" wnkey="absence%1:26:00::" text="The CDH gene exhibited a complete absence of expression in one cell line (SW756) that showed promoter hypermethylation and two other cell lines (C-33A and SiHa) without evidence of methylation (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="15665" end="15672" sStart="null" offset="43" sid="r11.absence.n.0384" wn="1" wnkey="absence%1:26:00::" text="The DAPK gene showed a complete absence of expression in five and down regulated expression in one of the 8 CC cell lines studied (Fig." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-24.anc" start="14972" end="14979" sStart="null" offset="55" sid="r11.absence.n.0029" wn="1" wnkey="absence%1:26:00::" text="The CDH gene exhibited a complete absence of expression in one cell line (SW756) that showed promoter hypermethylation and two other cell lines (C-33A and SiHa) without evidence of methylation (Fig." />
  </sentences>
</list>